Co-administration of tenofovir disoproxil (245 mg once daily) and doravirine (100 mg single dose) decreased doravirine AUC, Cmax and C24 by 5%, 20% and 6%, respectively. No dose adjustment is required.

No clinically significant changes in either drug concentration were observed when doravirine was co-administered with tenofovir disoproxil fumarate.

Co-administration of doravirine (100 mg single dose) with tenofovir-DF (300 mg once daily) was studied in 8 healthy male subjects. Doravirine AUC, Cmax and C24 decreased by 3%, 18% and 5%, respectively. The authors conclude that tenofovir-DF does not have not have a clinically relevant impact on doravirine pharmacokinetics.